Half-year report · HY
4465.TEDINET S100XFH2
Period2025-06-01 → 2025-11-30
Filed2026-01-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥12.1bn | 2025-06-01 → 2025-11-30 | Cons. | Net sales |
| Revenue | ¥23.7bn | 2024-06-01 → 2025-05-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥11.7bn | 2024-06-01 → 2024-11-30 | Cons. | Net sales |
| Operating income | ¥1.1bn | 2025-06-01 → 2025-11-30 | Cons. | Operating income |
| Operating income | ¥879m | 2024-06-01 → 2024-11-30 | Cons. | Operating income |
| Ordinary income | ¥1.2bn | 2025-06-01 → 2025-11-30 | Cons. | Ordinary income |
| Ordinary income | ¥2.0bn | 2024-06-01 → 2025-05-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥906m | 2024-06-01 → 2024-11-30 | Cons. | Ordinary income |
| Profit before tax | ¥1.3bn | 2025-06-01 → 2025-11-30 | Cons. | Income before income taxes |
| Profit before tax | ¥906m | 2024-06-01 → 2024-11-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥912m | 2025-06-01 → 2025-11-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥1.8bn | 2024-06-01 → 2025-05-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥608m | 2024-06-01 → 2024-11-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥912m | 2025-06-01 → 2025-11-30 | Cons. | Profit loss |
| Net income | ¥608m | 2024-06-01 → 2024-11-30 | Cons. | Profit loss |
| Total assets | ¥23.8bn | at 2025-11-30 | Cons. | Assets |
| Total assets | ¥22.6bn | at 2025-05-31 | Cons. | Assets |
| Total assets | ¥23.3bn | at 2024-11-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥8.2bn | at 2025-11-30 | Cons. | Liabilities |
| Total liabilities | ¥7.8bn | at 2025-05-31 | Cons. | Liabilities |
| Net assets / equity | ¥15.6bn | at 2025-11-30 | Cons. | Net assets |
| Net assets / equity | ¥14.8bn | at 2025-05-31 | Cons. | Net assets |
| Net assets / equity | ¥13.8bn | at 2024-11-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥7.3bn | at 2025-11-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥6.8bn | at 2025-05-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥6.9bn | at 2025-11-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥6.5bn | at 2025-05-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥6.3bn | at 2024-11-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥6.8bn | at 2024-05-31v | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥1.1bn | 2025-06-01 → 2025-11-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥1.0bn | 2024-06-01 → 2025-05-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥310m | 2024-06-01 → 2024-11-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥76m | 2025-06-01 → 2025-11-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥420m | 2024-06-01 → 2025-05-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥358m | 2024-06-01 → 2024-11-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥573m | 2025-06-01 → 2025-11-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥946m | 2024-06-01 → 2025-05-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥425m | 2024-06-01 → 2024-11-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥154.31 | 2025-06-01 → 2025-11-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥305.84 | 2024-06-01 → 2025-05-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥103.03 | 2024-06-01 → 2024-11-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 65.7% | at 2025-11-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 65.3% | at 2025-05-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 59.4% | at 2024-11-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 18
| Segment | Item | Period | Value |
|---|---|---|---|
| Chemical Businessreportable segment | revenue | 2025-06-01 → 2025-11-30 | ¥11.5bn |
| Chemical Businessreportable segment | revenue external | 2025-06-01 → 2025-11-30 | ¥11.5bn |
| Chemical Businessreportable segment | segment profit | 2025-06-01 → 2025-11-30 | ¥996m |
| Healthcare Businessreportable segment | revenue | 2025-06-01 → 2025-11-30 | ¥673m |
| Healthcare Businessreportable segment | revenue external | 2025-06-01 → 2025-11-30 | ¥673m |
| Healthcare Businessreportable segment | segment profit | 2025-06-01 → 2025-11-30 | ¥148m |
| —segment total | revenue | 2025-06-01 → 2025-11-30 | ¥12.1bn |
| —segment total | revenue external | 2025-06-01 → 2025-11-30 | ¥12.1bn |
| —segment total | segment profit | 2025-06-01 → 2025-11-30 | ¥1.1bn |
| Chemical Businessreportable segment | revenue | 2024-06-01 → 2024-11-30 | ¥11.0bn |
| Chemical Businessreportable segment | revenue external | 2024-06-01 → 2024-11-30 | ¥11.0bn |
| Chemical Businessreportable segment | segment profit | 2024-06-01 → 2024-11-30 | ¥731m |
| Healthcare Businessreportable segment | revenue | 2024-06-01 → 2024-11-30 | ¥671m |
| Healthcare Businessreportable segment | revenue external | 2024-06-01 → 2024-11-30 | ¥671m |
| Healthcare Businessreportable segment | segment profit | 2024-06-01 → 2024-11-30 | ¥148m |
| —segment total | revenue | 2024-06-01 → 2024-11-30 | ¥11.7bn |
| —segment total | revenue external | 2024-06-01 → 2024-11-30 | ¥11.7bn |
| —segment total | segment profit | 2024-06-01 → 2024-11-30 | ¥879m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 476
| Item | Context | Value | Unit |
|---|---|---|---|
| Repayment of long term loans payable fin cf | Prior1InterimDuration | -288593000 | JPY |
| Repayment of long term loans payable fin cf | InterimDuration | -260790000 | JPY |
| Redemption of bonds fin cf | Prior1InterimDuration | -5000000 | JPY |
| Redemption of bonds fin cf | InterimDuration | -5000000 | JPY |
| Cash dividends paid fin cf | Prior1InterimDuration | -129875000 | JPY |
| Cash dividends paid fin cf | InterimDuration | -306978000 | JPY |
| Repayments of lease obligations fin cf | Prior1InterimDuration | -1956000 | JPY |
| Repayments of lease obligations fin cf | InterimDuration | -339000 | JPY |
| Net cash provided by used in financing activities | Prior1InterimDuration | -425425000 | JPY |
| Net cash provided by used in financing activities | InterimDuration | -573108000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | Prior1InterimDuration | -12839000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | InterimDuration | 5653000 | JPY |
| Net increase decrease in cash and cash equivalents | Prior1InterimDuration | -486269000 | JPY |
| Net increase decrease in cash and cash equivalents | InterimDuration | 420521000 | JPY |
| Cash and cash equivalents | Prior2YearInstant | 6832763000 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 6490320000 | JPY |
| Cash and cash equivalents | Prior1InterimInstant | 6346493000 | JPY |
| Cash and cash equivalents | InterimInstant | 6910841000 | JPY |
| Employees salaries and bonuses sga | Prior1InterimDuration | 880343000 | JPY |
| Employees salaries and bonuses sga | InterimDuration | 894878000 | JPY |
| Retirement benefit expenses sga | Prior1InterimDuration | 49078000 | JPY |
| Retirement benefit expenses sga | InterimDuration | 44459000 | JPY |
| Freightage expenses sga | Prior1InterimDuration | 777409000 | JPY |
| Freightage expenses sga | InterimDuration | 773916000 | JPY |
| Revenues from external customers | Prior1InterimDuration_jpcrp040300-ssr_E00890-000ChemicalBusinessReportableSegmentsMember | 11019601000 | JPY |
| Revenues from external customers | Prior1InterimDuration_jpcrp040300-ssr_E00890-000HealthcareBusinessReportableSegmentsMember | 671474000 | JPY |
| Revenues from external customers | Prior1InterimDuration_ReportableSegmentsMember | 11691076000 | JPY |
| Revenues from external customers | Prior1InterimDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | Prior1InterimDuration | 11691076000 | JPY |
| Transactions with other segments | Prior1InterimDuration_jpcrp040300-ssr_E00890-000ChemicalBusinessReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1InterimDuration_jpcrp040300-ssr_E00890-000HealthcareBusinessReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1InterimDuration_ReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1InterimDuration_ReconcilingItemsMember | － | JPY |
| Transactions with other segments | Prior1InterimDuration | － | JPY |
| Net sales | Prior1InterimDuration_jpcrp040300-ssr_E00890-000ChemicalBusinessReportableSegmentsMember | 11019601000 | JPY |
| Net sales | Prior1InterimDuration_jpcrp040300-ssr_E00890-000HealthcareBusinessReportableSegmentsMember | 671474000 | JPY |
| Net sales | Prior1InterimDuration_ReportableSegmentsMember | 11691076000 | JPY |
| Net sales | Prior1InterimDuration_ReconcilingItemsMember | － | JPY |
| Net sales | Prior1InterimDuration | 11691076000 | JPY |
| Operating income | Prior1InterimDuration_jpcrp040300-ssr_E00890-000ChemicalBusinessReportableSegmentsMember | 730999000 | JPY |
| Operating income | Prior1InterimDuration_jpcrp040300-ssr_E00890-000HealthcareBusinessReportableSegmentsMember | 147655000 | JPY |
| Operating income | Prior1InterimDuration_ReportableSegmentsMember | 878654000 | JPY |
| Operating income | Prior1InterimDuration_ReconcilingItemsMember | － | JPY |
| Operating income | Prior1InterimDuration | 878654000 | JPY |
| Revenues from external customers | InterimDuration_jpcrp040300-ssr_E00890-000ChemicalBusinessReportableSegmentsMember | 11466076000 | JPY |
| Revenues from external customers | InterimDuration_jpcrp040300-ssr_E00890-000HealthcareBusinessReportableSegmentsMember | 673016000 | JPY |
| Revenues from external customers | InterimDuration_ReportableSegmentsMember | 12139093000 | JPY |
| Revenues from external customers | InterimDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | InterimDuration | 12139093000 | JPY |
| Transactions with other segments | InterimDuration_jpcrp040300-ssr_E00890-000ChemicalBusinessReportableSegmentsMember | － | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |